6 results about "Neuromuscular Blockade" patented technology

Neuromuscular block characterization techniques are disclosed. A muscle movement measurement device generates, unprompted by impulse stimulation to a subject from an external source, at least one signal representative of muscle movement measurements at at least one location of a body of the subject while the subject is experiencing neuromuscular paralysis caused by biophysiological processes at neuromuscular synapses throughout the body including remote from the at least one location. A processing circuit runs a neuromuscular block analysis module that receives the at least one signal, analyzes the muscle movement measurements embedded in the at least one signal, and determines a degree of neuromuscular blockade associated with the neuromuscular paralysis being experienced by the subject. The processing circuitry further generates, for display via a display device, an indication of the degree of the neuromuscular blockade at each said location on the body.

The present disclosure relates to compounds suitable for treating, ameliorating and / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.

The present invention relates to a biquaternary ammonium salt compound having an ultra-short-acting neuromuscular blocking function. In particular, the present invention relates to a compound represented by general formula (I-2), or a stereoisomer thereof, a pharmaceutically acceptable salt or co-crystal thereof, a pharmaceutically acceptable salt or co-crystal of the stereoisomer thereof, a solvate thereof, a prodrug thereof, a deuterated derivative thereof, or a metabolite thereof. The present invention also relates to a pharmaceutical composition containing the compound, a preparation method therefor, and the function and use thereof in neuromuscular blockade. Each substituent in the general formula (I-2) is as defined in the description.

A method for monitoring neuromuscular blockade is provided and includes: determining, based on an ultrasound image sequence of a target muscle in response to N consecutive electrical stimulations at equal intervals, temporal variation information of an architectural parameter of the target muscle, where N is an integer greater than 1; determining, based on the temporal variation information and in response to N consecutive electrical stimulations at equal intervals, a first change amount in the architectural parameter of the target muscle after an Nth electrical stimulation and a second change amount in the architectural parameter after a first electrical stimulation; determining a train-of-N ratio based on a ratio of the first change amount to the second change amount; and determining a degree of neuromuscular blockade based on a value of the train-of-N ratio.

The present disclosure relates to compounds suitable for treating, ameliorating and / or preventing neuromuscular disorders, including the reversal of drug-induced neuromuscular blockade. The compounds as defined herein can inhibit the CIC-1 ion channel.

The invention belongs to the technical field of biology, and particularly relates to a recombinant botulinum toxin A chimeric protein and application thereof. The recombinant A-type botulinum toxin chimeric protein is constructed by replacing only a C-terminal receptor binding domain or a whole receptor binding domain in a receptor structural domain on the basis of wild-type BoNT / A. The recombinant botulinum toxin A chimeric protein has substrate cleavage activity equivalent to that of wild toxin in vitro, can be effectively taken in Neuro-2a nerve cells and realize substrate cleavage, shows a significantly reduced toxicity level in animal bodies, and has a good application prospect. Wherein the AAAF chimeric protein has the characteristics of rapid effect taking and short action time, and is suitable for situations requiring short-term intervention of neural activity, such as short-term muscular tension regulation or local injection treatment; the AAFF chimeric protein has relatively long neuromuscular blocking duration and relatively high safety, and is suitable for long-term treatment of chronic nervous system diseases.